Latest News and Press Releases

JERUSALEM, March 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that Mira Rosenzweig, Chief Financial Officer, will be leaving the Company in mid-April 2019 on amicable...

JERUSALEM, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration (FDA) to discuss...

Entered into research collaboration and license agreement with Amgen, potential for up to $270 million in milestone payments, as well as royalties on commercial salesMet with FDA in late November 2018...

JERUSALEM, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) announced today the appointment of Gerald M. Ostrov as a new independent director on its Board of Directors, effective...

Amgen will have the option to advance up to three large molecule programs using Entera’s oral delivery technology Entera will be eligible to receive up to $270 million in clinical and commercial...

- - - Demonstrates positive results in three metabolic parameters in patients with hypoparathyroidism treated with Oral PTH (1-34) - - -Reports a significant decrease in 24-hour urinary calcium in...

JERUSALEM, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the appointment of Faith L. Charles and Miranda J. Toledano to the company’s board of directors,...

JERUSALEM, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) today announced the appointment of Arthur C. Santora II, MD, PhD as its new Chief Medical Officer, effective...

Closed Initial Public Offering on July 2, 2018Completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism Patients Mr. Gerald Lieberman was Appointed as Chairman of the Board of Directors ...

JERUSALEM, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW), announced today the appointment of Mr. Gerald Lieberman as the chairman of the board of directors, effective as...